Trial Profile

A Phase 2a Open-Label Study Assessing the Effectiveness, Safety, and Tolerability of OralDocarpamine in Patients with Refractory Ascites due to Liver Cirrhosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docarpamine (Primary)
Indications Ascites
Focus Therapeutic Use
Acronyms DREAM
Sponsors Martin Pharmaceuticals

Most Recent Events

03 Dec 2024 Results presented in the Martin Pharmaceuticals Media Release.
15 Nov 2024 According to a Martin Pharmaceuticals media release, the results from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD), in San Diego, California, from November 15-19, 2024.
15 Nov 2024 Results presented in the Martin Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com